Literature DB >> 19491277

Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor.

Yoriyuki Kamiryo1, Masatoshi Eto, Hisakata Yamada, Toshiki Yajima, Masahiko Harano, Ario Takeuchi, Katsunori Tatsugami, Masumitsu Hamaguchi, Seiji Naito, Yasunobu Yoshikai.   

Abstract

Nonmyeloablative allogeneic stem cell transplantation (SCT) has been used for various malignancies, although detailed mechanisms of antitumor effects remain unclear. We showed that a nonmyeloablative allogeneic SCT regimen, which consists of mixed chimerism induced by an injection of donor spleen and bone marrow cells followed by cyclophosphamide treatment and a donor lymphocyte infusion (DLI), exerted antitumor effects on established murine bladder tumor, MBT-2. An expansion of donor CD4 T cells accompanied by transient but vigorous IFN-gamma production was detected shortly after DLI. In vivo neutralization of IFN-gamma or depletion of CD4 T cells from DLI abolished the antitumor effects, indicating an indispensable role of donor CD4 T cells producing IFN-gamma. Donor as well as host CD8 T cells accumulated in the tumor region with time. Importantly, depletion of CD8 T cells from DLI did not reverse the suppression of tumor growth, indicating that CD4 T cells play a more essential role in mediating early antitumor effects. Furthermore, tumor-specific response of host CD8 T cells was suggested. These results not only provide the first evidence of nonmyeloablative allogeneic SCT for the treatment of bladder tumor but also elucidate detailed mechanisms of antitumor effects provoked by DLI.

Entities:  

Mesh:

Year:  2009        PMID: 19491277     DOI: 10.1158/0008-5472.CAN-08-2517

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors.

Authors:  David Barrett; Jonathan D Fish; Stephan A Grupp
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

2.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

3.  Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.

Authors:  S Ash; J Stein; N Askenasy; I Yaniv
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

4.  Gr-1 Ab administered after bone marrow transplantation plus thymus transplantation suppresses tumor growth by depleting granulocytic myeloid-derived suppressor cells.

Authors:  Ming Shi; Ming Li; Yunze Cui; Yasushi Adachi; Susumu Ikehara
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

5.  Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.

Authors:  Satoshi Ueha; Shoji Yokochi; Yoshiro Ishiwata; Mizuha Kosugi-Kanaya; Yusuke Shono; Shiro Shibayama; Satoru Ito; Kouji Matsushima
Journal:  Cancer Sci       Date:  2017-08-29       Impact factor: 6.716

6.  IFN-γ mediates graft-versus-breast cancer effects via enhancing cytotoxic T lymphocyte activity.

Authors:  Qianjie Zhao; Lingling Tong; Ningning He; Guowei Feng; Liang Leng; Weijun Sun; Yang Xu; Yuebing Wang; Rong Xiang; Zongjin Li
Journal:  Exp Ther Med       Date:  2014-06-05       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.